Share to FacebookShare to XArticle printing is available to subscribers onlyPrint in a simple, ad-free formatSubscribeComments: Zen reading is available to subscribers onlyAd-free and in a comfortable reading formatSubscribeTeva President and CEO Richard Francis. Credit: Elad MalkaTeva President and CEO Richard Francis. Credit: Elad Malka06:39 PM • June 10 2026 IDTTeva is set to lay off over a third of the 650 Israel-based employees in its Active Pharmaceutical Ingredients (TAPI) division, as part of a restructuring of the global unit, which was put up for sale as early as January 2024.TAPI operates 12 manufacturing plants and six research and development centers worldwide and employs about 4,000 people globally. It produces active pharmaceutical ingredients for 350 drugs supplied to 1,000 customers, with Teva itself serving as the division's largest customer. When the sale process was announced, the division's annual revenue was estimated at $1 billion, with 45 percent of sales generated from Teva's own internal demand.Teva Pharmaceuticals workers stand outside the Teva Medical offices in Ashdod, in Israel, in 2017. Credit: Amir Cohen/ ReutersTeva Pharmaceuticals workers stand outside the Teva Medical offices in Ashdod, in Israel, in 2017. Credit: Amir Cohen/ ReutersDemand for the division's products has declined in recent years. This is due both to Teva's accelerated transition from a company focused primarily on generic drugs to a biopharmaceutical company investing mainly in innovative medicines and biosimilars – produced in living cells that are highly similar to the original product – and to intensifying competition from active ingredient manufacturers in East Asia, particularly in chemical drugs where competition is fierce and profit margins are relatively low.Teva put the division up for sale at an estimated valuation of $1.5 billion, but efforts to sell it have so far failed. The company believes the unit will be easier to sell if it becomes more competitive.Teva's failure to complete the sale of TAPI is one of the reasons for the slower pace of reduction in its net financial debt, which stood at $12.9 billion at the end of March 2026, compared with $16.6 billion at the end of 2023, when the decision was made to sell the division.The restructuring process has already begun abroad, and Teva recently announced the closure of an active pharmaceutical ingredients plant in Italy. Reducing the number of TAPI manufacturing facilities is one of the measures Teva is taking to cut its total number of plants from 46 today to 40 by 2027, with the goal of lowering production costs and freeing up resources for further investment in innovative medicines.Teva building. Credit: Eliyahu HershkowitzTeva building. Credit: Eliyahu HershkowitzThe restructuring, which will be implemented gradually over the next two years, will focus on relatively profitable areas such as peptide manufacturing, while expanding operations in vitamins and oligonucleotide technology, which is used to produce active pharmaceutical ingredients based on DNA and RNA fragments. Drugs developed using this technology aim to address the genetic root causes of diseases rather than merely treating symptoms. The field is considered one of the growth engines of the TAPI industry, and Teva plans to focus the operations of its subsidiary Teva-Tech in Ramat Hovav on this area.Haaretz Podcast'Trump is paying a huge price domestically' for the Israel-Iran warHaaretz Podcast'Trump is paying a huge price domestically' for the Israel-Iran wartotal-- : --time0:00In 2022, Teva Pharmaceutical Industries announced a $4.35 billion nationwide settlement proposal in response to thousands of lawsuits over the drugmaker's alleged role in the U.S. opioid epidemic. The U.S. opioid crisis was responsible for over 80,000 deaths in 2021 alone, according to government data.In the NewsNetanyahu Aide Indicted for Severe Espionage Allegations, Faces Barring From PMOIsraeli Police Uses Legally Dubious Methods to Arrest and Deport EritreansHow Israel Is Using Archaeology to Advance West Bank AnnexationU.S.-Iran Talks Continue Despite Overnight Flare-up, Iranian Sources SayTo Lead the Middle East, Turkey's Erdogan Casts Israel as the Ultimate VillainRemembering and rebuilding two years laterICYMI'We Were Ordered to Kill': The 1967 Nakba That Israelis Don't Know AboutSix-year-old Boy Punctures a Magritte Iconic Masterpiece at Israel MuseumOne Killed, Five Wounded in Terror Shooting Rampage in Central IsraelGermany Is Paying a Price for Its Sweeping Support for IsraelIf the Netanyahu Government Falls, This Will Be the Reason'Server in the Sky': How Israeli Drones Became a 'Target Generator' Over Gaza